Canine parvovirus (CPV) virus-like particle (VLP) vaccines and uses thereof
The present invention encompasses canine parvovirus (CPV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing CPV virus-like particle (VLP), and a preparation method and a use thereof. The CPV VLPs provided by the invention are formed by the CPV VP2 protein. Further, the invention broadly encompasses vaccines comprising combinations of MLV and VLP, which are capable of overcoming MDA against a variety of pathogens, which infect a variety of different species.
1. A combination vaccine comprising a canine parvovirus (CPV) virus-like particle (VLP) component and a CPV modified-live virus (MLV) component, wherein both the VLP and the MLV are directed against the same pathogen or disease, wherein the combination vaccine overcomes CPV-specific, maternally-derived antibodies (MDA), wherein the pathogen is CPV; and wherein the CPV MLV and CPV VLP are present in amounts such that the CPV VLPs synergize the induction of an immune response with the CPV MLV in MDA+ puppies when administered simultaneously.
2. The combination vaccine of claim 1 , which provides protective immunity with a single dose.
3. The combination vaccine of claim 1 , wherein the CPVMLV component is a CPV-2 and the CPVVLP component is a CPV-2c.
4. The combination vaccine of claim 1 , further comprising a pharmaceutically or veterinarily acceptable carrier.
5. The combination vaccine of claim 3 , wherein the VLP component of the combination comprises at least 10% CPV VLPs (w/w) as a function of total protein content.
6. The combination vaccine of claim 5 , wherein the VLP component comprises at least 20% CPV VLPs (w/w).
7. The combination vaccine of claim 3 , wherein the CPV VLP is expressed by a baculovirus vector in insect cells.
8. The combination vaccine of claim 3 , wherein the CPV VLP comprises at least one CPV capsid protein.
9. The combination vaccine of claim 3 , wherein the CPV VLP comprises a CPV polypeptide having the sequence as set forth in SEQ ID NO: 1, 3, 4, 6, 8, 9 or 10; or, wherein the CPV VLP comprises a CPV polypeptide having at least 90% identity a sequence as set forth in SEQ ID NO: 1, 3, 4, 6, 8, 9 or 10.
10. The composition or vaccine of claim 1 , wherein the CPV VLP comprises a CPV polypeptide encoded by a polynucleotide having the sequence as set forth in SEQ ID NO: 2, 5 or 7; or,
wherein the CPV VLP comprises a CPV polypeptide encoded by a polynucleotide having at least 90% identity to a sequence as set forth in SEQ ID NO: 2, 5 or 7.
11. The combination vaccine of claim 1 , wherein the composition or vaccine is not adjuvanted and optionally comprises a pharmaceutically or veterinarily acceptable carrier, excipient, or vehicle.
12. A plasmid useful for producing CPV VLP, comprising a polynucleotide encoding a CPV antigen having a sequence as set forth in SEQ ID NO: 1, 3, 4, 6, or 8-10, or a polynucleotide sequence having at least 90% identity to a sequence as set forth in SEQ ID NO: 1, 3, 4, 6, or 8-10.
13. The plasmid of claim 12 , wherein the polynucleotide comprises or consists of the sequence as set forth in SEQ ID NO: 2, 5, 7, 11 or 12.
14. The plasmid of claim 12 , wherein the plasmid consists of the sequence as set forth in SEQ ID NO:11 or 12.
15. The plasmid of claim 12 , which is stably transformed into an insect cell, which expresses CPV VLPs.
16. A substantially purified CPV empty capsid or CPV VLP expressed in insect cells, wherein the CPV empty capsid or VLP comprises a polypeptide having a sequence as set forth in SEQ ID NO: 1, 3, 4, 6, or 8-10; or,
wherein the CPV empty capsid or VLP comprises a polypeptide having at least 90% identity to a sequence as set forth in SEQ ID NO: 1, 3, 4, 6, or 8-10.
17. The purified CPV empty capsid or CPV VLP of claim 16 , wherein the CPV empty capsid or VLP consists of a polypeptide having a sequence as set forth in SEQ ID NO: 1, 3, 4, 6, or 8-10.
18. A method of vaccinating an animal against CPV comprising administering to the animal the composition of any one of claims 1 - 7 , or the CPV empty capsids or VLPs of claim 16 .
19. The method of claim 18 , wherein the immune response is protective, and wherein the protective immune response protects vaccinated animals against subsequent exposure to virulent CPV.
20. The method of claim 19 , wherein the protective immune response is elicited in the vaccinated animals, regardless of the presence in said animals of high levels of maternally-derived antibodies (MDA) against CPV.